查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1875881

全球GMP細胞庫服務市場

GMP Cell Banking Services
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球GMP細胞庫服務市場預計2030年將達22億美元

全球GMP細胞庫服務市場規模在2024年估計為9.394億美元，預計到2030年將達到22億美元，在分析期（2024-2030年）內複合年成長率（CAGR）為15.0%。本報告分析的細分市場之一「生物製藥公司」預計將以14.6%的複合年成長率成長，並在分析期間結束時達到15億美元。同時，「契約製造組織」細分市場預計在分析期間內將以16.0%的複合年成長率成長。

美國市場規模估計為2.606億美元，而中國市場預計將以14.0%的複合年成長率成長。

預計到2024年，美國符合GMP標準的細胞庫服務市場規模將達到2.606億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到3.282億美元，在2024年至2030年的分析期內，複合年成長率（CAGR）將達到14.0%。其他值得關注的區域市場分析包括日本和加拿大，預計在分析期內，這兩個國家的複合年成長率將分別達到13.0%和12.8%。在歐洲，德國預計將以約10.7%的複合年成長率成長。

全球GMP細胞庫服務市場—關鍵趨勢與促進因素概述

為什麼符合GMP標準的細胞庫服務在生物製藥開發和治療中變得越來越重要？

由於生物製藥行業對安全、可靠、高品質的細胞株的需求日益成長，GMP細胞庫服務正變得至關重要。那麼，為什麼這些服務在今天如此重要呢？ GMP（良好生產規範）細胞庫是指在嚴格的監管和品管標準下建立、保存和維護細胞株。這些服務確保用於生產生物製藥、疫苗、基因療法和其他治療藥物的細胞株不受污染，並能長期保持其完整性。

細胞株在生物製藥研發中發揮著至關重要的作用，尤其是在單株抗體、重組蛋白和基因治療病毒載體的生產方面。符合GMP標準的細胞庫建立流程包括建立主細胞庫（MCB）和工作細胞庫（WCB），這對於生物製藥的規模化生產至關重要。細胞株在受控條件下儲存，以維持其活性和遺傳穩定性，從而確保多個生產批次的一致性。鑑於FDA和EMA等監管機構的要求，GMP細胞庫對於滿足合規標準、確保治療藥物的安全性和有效性以及加快產品上市速度至關重要。隨著生物製藥產業隨著生物製藥和個人化醫療的興起而不斷發展，GMP細胞庫服務已成為安全可靠生產這些先進治療方法的關鍵組成部分。

科技進步如何提升GMP細胞庫服務？

技術創新在提升GMP細胞庫服務的效率、安全性和擴充性方面發揮了關鍵作用，使生物製藥公司能夠更輕鬆地維持用於治療藥物生產的高品質細胞株。其中一項最具影響力的進展是自動化細胞培養系統的引入，該系統能夠實現更精確、更可重複的細胞庫建構過程。自動化減少了人為誤差，並最大限度地降低了污染風險和細胞株特性變異性，因為細胞庫的製備、監測和維護均在最佳條件下進行。這在大規模生產環境中尤其重要，因為在這些環境中，一致性至關重要。

冷凍保存技術的進步使得細胞株的長期保存成為可能，且不會損害細胞的活性或功能。改良的冷凍保護劑配方和冷凍通訊協定提高了在超低溫下保存細胞的能力，並降低了冰晶形成的風險，從而避免了冰晶對細胞的損傷。這些進步使得細胞庫能夠在長期（通常長達數十年）內保持細胞活性，同時保持其遺傳和表現型的完整性。這對於生物製造程序的可重複性至關重要，尤其是在需要多年穩定供應高品質細胞的情況下。

將先進的分析和品管技術整合到GMP細胞庫中，正在徹底改變這一領域。諸如次世代定序（NGS）、流式細胞技術和數位PCR（dPCR）等技術正被用於更全面地表徵細胞株，確保其不含黴漿菌和病毒等污染物，並維持其遺傳特性。這些先進的分析技術能夠對細胞庫品質進行更嚴格的監控，為生物製藥公司提供關於其細胞株健康狀況和穩定性的詳細資訊。這種程度的控制對於基因療法和細胞療法等先進治療方法的開發尤其重要，因為即使細胞株存在細微的差異，也可能影響最終產品的療效和安全性。

此外，文件和資料管理系統的進步正在提升GMP細胞庫服務的可追溯性和合規性。現代軟體平台能夠對所有細胞庫流程進行全面記錄，涵蓋從初始表徵到冷凍保存和儲存的各個環節。這些系統使生物製藥公司能夠輕鬆追蹤其細胞庫的歷史記錄，確保符合監管指南，並方便FDA和EMA等機構的審核。對細胞株進行完全控制和可追溯性驗證的能力，對於獲得生物製藥的監管核准以及確保治療產品的長期成功至關重要。

為什麼GMP細胞庫服務對於確保生物製藥的安全性、穩定性和可擴展性至關重要？

GMP細胞庫服務對於確保生物製藥的安全性、穩定性和可擴展性至關重要，因為它們提供了一個可控且合規的系統，用於生產一致的高品質治療產品。在單株抗體、疫苗和基因療法等生物製藥的生產過程中，細胞株係被用作生物工廠來生產這些複雜的分子。確保這些細胞株無污染、遺傳穩定且具有可重複的性能，對於生物製藥的成功開發和生產至關重要。

在生物製藥產業，安全是重中之重，而符合GMP標準的細胞庫服務對於降低細胞株污染和變異性的風險至關重要。細菌、病毒和黴漿菌等污染物會損害生物製藥的安全性和有效性，導致不良患者後果和監管召回。 GMP細胞庫確保細胞株在用於生產治療產品之前經過徹底的檢測和檢驗，不含污染物。這種嚴格的檢測和監控流程降低了污染風險，確保生物製藥公司能夠為患者生產安全可靠的生物製藥產品。

穩定性是GMP細胞庫的另一個關鍵優勢。生物製藥必須長期穩定生產，通常需要多個生產批次，以滿足臨床試驗和商業化的需求。建立主細胞庫（MCB）和工作細胞庫（WCB）可確保生產中使用的細胞株在遺傳上保持穩定，功能上長期可靠。透過冷凍保存主細胞庫並以此為基礎建立工作細胞庫，生物製藥公司即使在細胞株最初建立數年後，也能維持其生產流程的一致性。這種穩定性對於維持生物製藥在其整個生命週期內的品質和療效至關重要。

對於商業生物製藥生產而言，可擴展性至關重要，因為大規模生產治療藥物的能力是滿足市場需求的必要條件。 GMP細胞庫服務透過提供穩定、可擴展的高品質細胞株，協助生物製藥的大規模生產。生物製藥公司利用主細胞庫建立工作細胞庫，從而獲得充足的細胞供應，這些細胞可以放大生產規模，用於任何規模的生產。這種擴充性在基因療法和細胞療法等先進治療方法的開發中尤其重要，因為在這些療法中，能夠以穩定的批次生產大量細胞是商業性成功的關鍵。

此外，符合GMP標準的細胞庫服務透過遵循嚴格的品管和文件記錄標準，幫助生物製藥公司滿足監管要求。生物製藥公司在將生物製藥推向市場之前，必須向監管機構證明其細胞株安全、穩定且特性明確。符合GMP標準的細胞庫提供滿足這些監管要求所需的文件和可追溯性，確保生物製藥公司能夠有效率地完成核准流程。如果沒有符合GMP標準的細胞庫，將難以達到監管機構設定的嚴格標準，進而危及生物製藥的研發和商業化。

哪些因素正在推動符合GMP標準的細胞庫服務市場的成長？

推動GMP細胞庫服務市場成長的關鍵因素包括：對生物製藥和先進治療方法的需求不斷成長、個人化醫療的興起、全球臨床試驗的擴展以及生物製藥開發監管環境的日益嚴格。首先，對生物製藥（例如單株抗體、疫苗和基因療法）的需求不斷成長是GMP細胞庫市場的主要驅動力。隨著生物製藥公司拓展產品線並納入更多生物製藥，對可靠且合規的細胞庫服務的需求也日益成長，以支持這些複雜治療藥物的生產。細胞庫對於確保生物製藥在研發、臨床試驗和商業化生產過程中的一致性和品質至關重要。

其次，個人化醫療的興起推動了對GMP細胞庫服務的需求。個人化療法，例如CAR-T細胞療法和基因編輯療法，通常需要使用患者特異性或基因工程改造的細胞株。 GMP細胞庫服務在維持這些細胞株的品質和安全性方面發揮著至關重要的作用，確保其在個人化療法中保持穩定狀態。隨著生物製藥產業不斷向個人化醫療轉型，對高品質GMP細胞庫以支持患者特異性生物製藥生產的需求只會不斷成長。

全球臨床試驗的擴展也是推動GMP細胞庫市場成長的因素之一。隨著臨床試驗日益國際化並覆蓋更廣泛的患者群體，生物製藥公司必須擴大產能以滿足不斷成長的治療產品需求。 GMP細胞庫服務提供必要的基礎設施，能夠大規模生產穩定、高品質的生物製藥，確保臨床試驗不會因供不應求或品質問題而中斷。此外，隨著更多先進治療方法進入臨床試驗階段，對特性明確、符合GMP規範的細胞庫的需求也日益重要。

生物製藥研發領域嚴格的監管環境也推動了對符合GMP標準的細胞庫服務的需求。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構要求生物製藥公司證明其用於生物製藥生產的細胞株符合嚴格的品質標準。符合GMP標準的細胞庫確保這些細胞株經過全面測試、記錄完整併符合監管指南，從而降低核准流程延誤的風險。隨著生物製藥監管要求的日益複雜，預計對符合GMP標準的細胞庫服務的需求將進一步成長。

總之，GMP細胞庫服務市場的成長主要受以下因素驅動：生物製藥和先進治療方法需求的不斷成長、個人化醫療的興起、全球臨床試驗的擴展以及生物製藥開發監管環境的日益嚴格。隨著生物製藥產業的不斷發展，並日益重視高品質、安全有效的治療藥物的生產，GMP細胞庫服務將在支持這些救命治療方法的開發和商業化方面發揮核心作用。

部分：

細胞類型（哺乳動物、微生物、酵母、昆蟲、禽類、其他細胞類型），最終用途（生物製藥公司、契約製造組織）

受訪公司範例

  • Austrianova Singapore Pte Ltd.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific SE
  • Goodwin Biotechnology, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Paragon Bioservices, Inc.
  • SGS India Pvt. Ltd.
  • ViruSure GmbH
  • WuXi AppTec

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，革新市場和競爭情報分析。

Market Glass, Inc. 並沒有採用查詢LLM 或產業專用的SLM 的常見做法，而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片文字稿、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

在最新發布的報告中，Market Glass, Inc. 將關稅對地理市場的影響納入考量，並根據公司總部所在國、製造地以及進出口（成品和OEM產品）情況，預測企業競爭格局的變化。這種複雜多變的市場現實將對競爭對手產生多方面的影響，包括銷貨成本增加、盈利下降和供應鏈重組，同時也會影響微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 世界其他地區

第4章 競賽

簡介目錄
Product Code: MCP12206

Global GMP Cell Banking Services Market to Reach US$2.2 Billion by 2030

The global market for GMP Cell Banking Services estimated at US$939.4 Million in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Biopharmaceutical Companies End-Use, one of the segments analyzed in the report, is expected to record a 14.6% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Contract Manufacturing Organizations End-Use segment is estimated at 16.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$260.6 Million While China is Forecast to Grow at 14.0% CAGR

The GMP Cell Banking Services market in the U.S. is estimated at US$260.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$328.2 Million by the year 2030 trailing a CAGR of 14.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.0% and 12.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.7% CAGR.

Global GMP Cell Banking Services Market - Key Trends and Drivers Summarized

Why Are GMP Cell Banking Services Becoming Crucial in Biopharmaceutical Development and Therapeutics?

GMP cell banking services are becoming essential in the biopharmaceutical industry due to the increasing demand for safe, reliable, and high-quality cell lines for therapeutic development. But why are these services so critical today? GMP (Good Manufacturing Practice) cell banking refers to the creation, storage, and maintenance of cell lines under stringent regulatory and quality control standards. These services ensure that cell lines used in the production of biologics, vaccines, gene therapies, and other therapeutics are free from contamination and retain their integrity over time.

In biopharmaceutical development, the use of cell lines is foundational, particularly in the production of monoclonal antibodies, recombinant proteins, and viral vectors for gene therapy. The process of GMP cell banking involves generating master cell banks (MCBs) and working cell banks (WCBs), which are critical for scaling up the production of biologics. Cell lines are preserved under controlled conditions to maintain their viability and genetic stability, ensuring consistency across multiple production batches. Given the regulatory requirements from agencies such as the FDA and EMA, GMP cell banking is indispensable for meeting compliance standards, ensuring the safety and efficacy of therapeutics, and accelerating their path to market. As the biopharmaceutical industry continues to expand with the rise of biologics and personalized medicine, GMP cell banking services are integral to the safe and reliable production of these advanced therapies.

How Are Technological Advancements Enhancing GMP Cell Banking Services?

Technological advancements are playing a significant role in improving the efficiency, safety, and scalability of GMP cell banking services, making it easier for biopharmaceutical companies to maintain high-quality cell lines for therapeutic production. One of the most impactful advancements is the use of automated cell culture systems, which allow for more precise and reproducible cell banking processes. Automation reduces human error and ensures that cell banks are prepared, monitored, and maintained under optimal conditions, minimizing the risk of contamination or variation in cell line characteristics. This is particularly important in large-scale production environments where consistency is critical.

Cryopreservation techniques have also advanced, allowing for the long-term storage of cell lines without compromising their viability or functionality. Improvements in cryoprotectant formulations and freezing protocols have enhanced the ability to store cells at ultra-low temperatures, reducing the risk of ice crystal formation, which can damage cells. These advancements ensure that cell banks remain viable for extended periods, often decades, while preserving their genetic and phenotypic integrity. This is vital for the reproducibility of biologic manufacturing processes, especially when a consistent supply of high-quality cells is required over the course of several years.

The integration of advanced analytics and quality control technologies into GMP cell banking is also revolutionizing the field. Techniques such as next-generation sequencing (NGS), flow cytometry, and digital PCR (dPCR) are being used to characterize cell lines more thoroughly, ensuring that they are free from contaminants like mycoplasma or viruses and that their genetic identity is preserved. These advanced analytics allow for better monitoring of cell bank quality, providing biopharmaceutical companies with detailed information on the health and stability of their cell lines. This level of control is particularly important in the development of advanced therapies like gene and cell therapies, where even minor variations in the cell line can impact the efficacy and safety of the final product.

Additionally, advancements in documentation and data management systems are improving the traceability and regulatory compliance of GMP cell banking services. Modern software platforms allow for the comprehensive documentation of all processes involved in cell banking, from initial characterization to cryopreservation and storage. These systems make it easier for biopharmaceutical companies to track the history of their cell banks, ensuring compliance with regulatory guidelines and facilitating audits by agencies like the FDA or EMA. The ability to demonstrate full control and traceability over cell lines is essential for gaining regulatory approval for biologics and ensuring the long-term success of therapeutic products.

Why Are GMP Cell Banking Services Critical for Ensuring the Safety, Stability, and Scalability of Biologics?

GMP cell banking services are critical for ensuring the safety, stability, and scalability of biologics because they provide a controlled and compliant system for producing consistent, high-quality therapeutic products. In the production of biologics-such as monoclonal antibodies, vaccines, and gene therapies-cell lines are used as the biological factories that produce these complex molecules. Ensuring that these cell lines are free from contamination, genetically stable, and capable of reproducible performance is essential for the successful development and manufacturing of biologics.

Safety is a primary concern in the biopharmaceutical industry, and GMP cell banking services are crucial for mitigating risks related to contamination and variability in cell lines. Contaminants such as bacteria, viruses, and mycoplasma can compromise the safety and efficacy of biologics, potentially leading to adverse patient outcomes or regulatory recalls. GMP cell banking ensures that cell lines are thoroughly tested and validated for the absence of contaminants before being used in the production of therapeutic products. This rigorous testing and monitoring process reduces the risk of contamination and ensures that biopharmaceutical companies can produce safe, reliable biologics for patients.

Stability is another key benefit provided by GMP cell banking. Biologics must be produced consistently over time, often across multiple manufacturing batches, to meet the demands of clinical trials and commercialization. The establishment of master and working cell banks guarantees that the cell lines used in production remain genetically stable and functionally reliable over time. By cryopreserving the master cell bank (MCB) and creating working cell banks (WCB) from this source, biopharmaceutical companies can ensure that their production processes remain consistent, even years after the initial creation of the cell line. This stability is essential for maintaining the quality and efficacy of biologics throughout their lifecycle.

Scalability is also critical in the commercial production of biologics, where the ability to produce large quantities of therapeutic products is essential for meeting market demand. GMP cell banking services enable the large-scale production of biologics by providing a consistent and scalable supply of high-quality cell lines. The creation of working cell banks from a master cell bank ensures that biopharmaceutical companies have a ready supply of cells that can be expanded and used for manufacturing at any scale. This scalability is particularly important in the development of advanced therapies like gene and cell therapies, where the ability to produce consistent batches of cells at large volumes is key to commercial success.

Additionally, GMP cell banking services support regulatory compliance by adhering to strict quality control and documentation standards. Biopharmaceutical companies must demonstrate to regulatory agencies that their cell lines are safe, stable, and well-characterized before they can bring biologics to market. GMP-compliant cell banks provide the necessary documentation and traceability to meet these regulatory requirements, ensuring that biopharmaceutical companies can navigate the approval process efficiently. Without GMP cell banking, it would be challenging to meet the rigorous standards set by regulatory agencies, putting the development and commercialization of biologics at risk.

What Factors Are Driving the Growth of the GMP Cell Banking Services Market?

Several key factors are driving the growth of the GMP cell banking services market, including the increasing demand for biologics and advanced therapies, the rise of personalized medicine, the expansion of clinical trials globally, and the stringent regulatory environment governing biopharmaceutical development. First, the growing demand for biologics-such as monoclonal antibodies, vaccines, and gene therapies-is a major driver of the GMP cell banking market. As biopharmaceutical companies expand their pipelines to include more biologics, there is an increasing need for reliable and compliant cell banking services to support the production of these complex therapeutics. Cell banks are critical for ensuring the consistency and quality of biologics throughout their development, clinical trials, and commercial production.

Second, the rise of personalized medicine is contributing to the demand for GMP cell banking services. Personalized therapies, such as CAR-T cell therapies and gene-editing treatments, often require the use of patient-specific or genetically engineered cell lines. GMP cell banking services play a key role in maintaining the quality and safety of these cell lines, ensuring that they remain stable and viable for use in personalized treatments. As the biopharmaceutical industry continues to shift toward individualized therapies, the need for high-quality GMP cell banks will grow to support the production of patient-specific biologics.

The expansion of clinical trials globally is another factor driving the growth of the GMP cell banking market. As clinical trials become more international and involve larger patient populations, biopharmaceutical companies must scale up their production capabilities to meet the increased demand for therapeutic products. GMP cell banking services provide the infrastructure needed to produce consistent, high-quality biologics at scale, ensuring that clinical trials can proceed without interruptions due to supply shortages or quality issues. Additionally, as more advanced therapies enter clinical trials, the need for well-characterized, GMP-compliant cell banks is becoming even more critical.

The stringent regulatory environment governing biopharmaceutical development is also fueling the demand for GMP cell banking services. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require biopharmaceutical companies to demonstrate that their cell lines meet strict quality standards before they can be used in the production of biologics. GMP cell banking ensures that these cell lines are thoroughly tested, documented, and compliant with regulatory guidelines, reducing the risk of delays in the approval process. As regulatory requirements for biologics become more complex, the demand for GMP-compliant cell banking services is expected to grow.

In conclusion, the growth of the GMP cell banking services market is driven by the increasing demand for biologics and advanced therapies, the rise of personalized medicine, the expansion of global clinical trials, and the stringent regulatory environment governing biopharmaceutical development. As the biopharmaceutical industry continues to evolve and prioritize the production of high-quality, safe, and effective therapeutics, GMP cell banking services will play a central role in supporting the development and commercialization of these life-saving treatments.

SCOPE OF STUDY:

The report analyzes the GMP Cell Banking Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cell Type (Mammalian, Microbial, Yeast, Insect, Avian, Other Cell Types); End-Use (Biopharmaceutical Companies, Contract Manufacturing Organizations)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Austrianova Singapore Pte Ltd.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific SE
  • Goodwin Biotechnology, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Paragon Bioservices, Inc.
  • SGS India Pvt. Ltd.
  • ViruSure GmbH
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • GMP Cell Banking Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for GMP Cell Banking Services Driven by Growth in Biopharmaceuticals
    • Innovations in Cell Preservation and Storage Techniques Enhance Service Offerings
    • Growth in Outsourcing of Cell Banking Services by Pharmaceutical Companies
    • Market Opportunities in Emerging Regions with Expanding Healthcare Sectors
    • Consumer Trends Toward Advanced Therapeutic Medicinal Products (ATMPs)
    • Future Directions: Integration of Blockchain for Traceability in Cell Banking
    • Innovations in Cryopreservation Technologies for Enhanced Cell Recovery
    • Impact of Biobanking on the Development of Regenerative Medicine
    • Expansion of Cell Banks for Rare Disease Research and Therapy Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Contract Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Contract Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Microbial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Microbial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Yeast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Yeast by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Insect by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Insect by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Avian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Avian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World GMP Cell Banking Services Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for GMP Cell Banking Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for GMP Cell Banking Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • JAPAN
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • CHINA
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 34: China Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • EUROPE
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 36: Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for GMP Cell Banking Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 42: France Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 44: France Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • GERMANY
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 46: Germany Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 48: Germany Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 52: Italy Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • UNITED KINGDOM
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 54: UK Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 56: UK Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • ASIA-PACIFIC
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of World 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 68: Rest of World Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of World 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030

IV. COMPETITION